Faithward Advisors LLC Takes $2.16 Million Position in Mirum Pharmaceuticals, Inc. $MIRM

Faithward Advisors LLC acquired a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the fourth quarter, HoldingsChannel reports. The firm acquired 27,341 shares of the company’s stock, valued at approximately $2,160,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC increased its position in Mirum Pharmaceuticals by 6.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after purchasing an additional 200 shares in the last quarter. Jones Financial Companies Lllp increased its position in Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after purchasing an additional 243 shares in the last quarter. Comerica Bank increased its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. Osaic Holdings Inc. increased its position in Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock worth $56,000 after purchasing an additional 351 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $30,000.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Stifel Nicolaus set a $136.00 price objective on Mirum Pharmaceuticals in a research report on Thursday, May 7th. Robert W. Baird lifted their price objective on Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, May 7th. Wolfe Research assumed coverage on Mirum Pharmaceuticals in a research report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price objective for the company. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $139.80.

Mirum Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ:MIRM opened at $101.00 on Tuesday. The stock’s 50-day moving average price is $98.02 and its two-hundred day moving average price is $91.47. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $47.89 and a 12-month high of $114.99. The firm has a market cap of $6.16 billion, a price-to-earnings ratio of -7.42 and a beta of 0.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The business had revenue of $159.88 million during the quarter, compared to analyst estimates of $148.21 million. During the same period in the previous year, the business posted ($0.30) earnings per share. The firm’s quarterly revenue was up 43.3% on a year-over-year basis. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $93.82, for a total value of $469,100.00. Following the sale, the chief financial officer directly owned 44,788 shares of the company’s stock, valued at approximately $4,202,010.16. This trade represents a 10.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the completion of the transaction, the chief executive officer owned 194,309 shares in the company, valued at approximately $18,622,574.56. This trade represents a 13.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 8.32% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.